Endovascular revascularization has been increasingly utilized to treat patients with chronic limb-threatening ischemia (CLTI), particularly atherosclerotic disease in the infrapopliteal arteries. Lesions of the infrapopliteal arteries are the result of 2 different etiologies: medial calcification and intimal atheromatous plaque. Although several devices are available for endovascular treatment of infrapopliteal lesions, balloon angioplasty still comprises the mainstay of therapy due to a lack of purpose-built devices. The mechanism of balloon angioplasty consists of adventitial stretching, medial necrosis, and dissection or plaque fracture. In many cases, the diffuse nature of infrapopliteal disease and plaque complexity may lead to dissection, recoil, and early restenosis. Optimal balloon angioplasty requires careful attention to assessment of vessel calcification, appropriate vessel sizing, and the use of long balloons with prolonged inflation times, as outlined in a treatment algorithm based on this systematic review. Further development of specific devices for this arterial segment are warranted, including devices for preventing recoil (eg, dedicated atherectomy devices), treating dissections (eg, tacks, stents), and preventing neointimal hyperplasia (eg, novel drug delivery techniques and drug-eluting stents). Further understanding of infrapopliteal disease, along with the development of new technologies, will help optimize the durability of endovascular interventions and ultimately improve the limb-related outcomes of patients with CLTI.
SinghSArmstrongEJSherifW, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med. 2014;19:307–314.
2.
WestinGGArmstrongEJBangH, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682–690.
3.
ShammasANJeon-SlaughterHTsaiS, et al. Major limb outcomes following lower extremity endovascular revascularization in patients with and without diabetes mellitus. J Endovasc Ther. 2017;24:376–382.
4.
ShishehborMHWhiteCJGrayBH, et al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–2015.
5.
Abu DabrhAMSteffenMWUndavalliC, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62:1642–1651.e3.
6.
BisdasTBorowskiMTorselloG.Current practice of first-line treatment strategies in patients with critical limb ischemia. J Vasc Surg. 2015;62:965–973.e3.
FowkesFGRudanDRudanI, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.
9.
SachsTPomposelliFHamdanA, et al. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. J Vasc Surg. 2011;54:1021–1031.e1.
10.
NorgrenLHiattWRDormandyJA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
11.
NorgrenLHiattWRDormandyJA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–S75.
12.
SaraidaridisJTErgulEPatelVI, et al. The Society for Vascular Surgery’s objective performance goals for lower extremity revascularization are not generalizable to many open surgical bypass patients encountered in contemporary surgical practice. J Vasc Surg. 2015;62:392–400.
13.
TASC Steering Committee, JaffMRWhiteCJ, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.
14.
GoodneyPPBeckAWNagleJ, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.
15.
AboyansVRiccoJBBartelinkMEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
16.
SchampKBMeerwaldtRReijnenMM, et al. The ongoing battle between infrapopliteal angioplasty and bypass surgery for critical limb ischemia. Ann Vasc Surg. 2012;26:1145–1153.
17.
KondapalliAJeon-SlaughterHLuH, et al. Comparative assessment of patient outcomes with intraluminal or subintimal crossing of infrainguinal peripheral artery chronic total occlusions. Vasc Med. 2018;23:39–45.
18.
DeRubertisBGFariesPLMcKinseyJF, et al. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg. 2007;246:415–422.
19.
LairdJRJainAZellerT, et al. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014;21:202–212.
20.
SchillingerMSabetiSDickP, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.
21.
SinghGDBrinzaEKHildebrandJ, et al. Midterm outcomes after infrapopliteal interventions in patients with critical limb ischemia based on the TASC II classification of below-the-knee arteries. J Endovasc Ther. 2017;24:321–330.
22.
RomitiMAlbersMBrochado-NetoFC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–981.
23.
KatsanosKKitrouPSpiliopoulosS, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.
24.
GiordanoAPeruzziMFratiG, et al. Commentary: Identifying the best device for infrapopliteal revascularization through quantitative evidence synthesis. J Endovasc Ther. 2016;23:864–866.
25.
BosiersMHartJPDelooseK, et al. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular. 2006;14:63–69.
26.
Castaneda-ZunigaWRFormanekATadavarthyM, et al. The mechanism of balloon angioplasty. Radiology. 1980;135:565–571.
27.
DotterCTJudkinsMP.Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation. 1964;30:654–670.
28.
FaxonDPWeberVJHaudenschildC, et al. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis. 1982;2:125–133.
29.
BlockPCBaughmanKLPasternakRC, et al. Transluminal angioplasty: correlation of morphologic and angiographic findings in an experimental model. Circulation. 1980;61:778–785.
30.
HoshinoTYoshidaHTakayamaS, et al. Significance of intimal tears in the mechanism of luminal enlargement in percutaneous transluminal coronary angioplasty: correlation of histologic and angiographic findings in postmortem human hearts. Am Heart J. 1987;114:503–510.
31.
LyonRTZarinsCKLuCT, et al. Vessel, plaque, and lumen morphology after transluminal balloon angioplasty. Quantitative study in distended human arteries. Arteriosclerosis. 1987;7:306–314.
32.
BaughmanKLPasternakRCFallonJT, et al. Transluminal coronary angioplasty of postmortem human hearts. Am J Cardiol. 1981;48:1044–1047.
33.
SanbornTAFaxonDPHaudenschildC, et al. The mechanism of transluminal angioplasty: evidence for formation of aneurysms in experimental atherosclerosis. Circulation. 1983;68:1136–1140.
34.
BotasJClarkDAPintoF, et al. Balloon angioplasty results in increased segmental coronary distensibility: a likely mechanism of percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1043–1052.
35.
TenagliaANBullerCEKissloKB, et al. Mechanisms of balloon angioplasty and directional coronary atherectomy as assessed by intracoronary ultrasound. J Am Coll Cardiol. 1992;20:685–691.
36.
DavidsonCJNewmanGESheikhKH, et al. Mechanisms of angioplasty in hemodialysis fistula stenoses evaluated by intravascular ultrasound. Kidney Int. 1991;40:91–95.
37.
MustaphaJADiaz-SandovalLJSaabF.Infrapopliteal calcification patterns in critical limb ischemia: diagnostic, pathologic and therapeutic implications in the search for the endovascular holy grail. J Cardiovasc Surg (Torino). 2017;58:383–401.
38.
GuzmanRJBrinkleyDMSchumacherPM, et al. Tibial artery calcification as a marker of amputation risk in patients with peripheral arterial disease. J Am Coll Cardiol. 2008;51:1967–1974.
39.
RaptisSFergusonLMillerJH.The significance of tibial artery disease in the management of popliteal aneurysms. J Cardiovasc Surg (Torino). 1986;27:703–708.
40.
GrayBHGrantAAKalbaughCA, et al. The impact of isolated tibial disease on outcomes in the critical limb ischemic population. Ann Vasc Surg. 2010;24:349–359.
41.
SadekMEllozySHTurnbullIC, et al. Improved outcomes are associated with multilevel endovascular intervention involving the tibial vessels compared with isolated tibial intervention. J Vasc Surg. 2009;49:638–643.
42.
GrazianiLSilvestroABertoneV, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg. 2007;33:453–460.
43.
FernandezNMcEnaneyRMaroneLK, et al. Multilevel versus isolated endovascular tibial interventions for critical limb ischemia. J Vasc Surg. 2011;54:722–729.
44.
BishopPDFeitenLEOurielK, et al. Arterial calcification increases in distal arteries in patients with peripheral arterial disease. Ann Vasc Surg. 2008;22:799–805.
ShanahanCMCaryNRSalisburyJR, et al. Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168–2176.
47.
LondonGMGuerinAPMarchaisSJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740.
48.
TripodiA.Thrombin generation assay and its application in the clinical laboratory. Clin Chem. 2016;62:699–707.
49.
KuijpersMJvan der MeijdenPEFeijgeMA, et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol. 2014;34:1674–1680.
50.
DalagerSPaaskeWPKristensenIB, et al. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke. 2007;38:2698–2705.
51.
AboyansVLacroixPCriquiMH.Large and small vessels atherosclerosis: similarities and differences. Prog Cardiovasc Dis. 2007;50:112–125.
52.
SteenmanMEspitiaOMaurelB, et al. Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries. Sci Rep. 2018;8:3940.
53.
HerissonFHeymannMFChetiveauxM, et al. Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis. 2011;216:348–354.
54.
HeymannMFHerissonFDavaineJM, et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine. 2012;58:300–306.
ErbelRSchmermundA.Clinical significance of coronary calcification. Arterioscler Thromb Vasc Biol. 2004;24:e172.
57.
HuangHVirmaniRYounisH, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation. 2001;103:1051–1056.
58.
WaxmanSDixonSRL’AllierP, et al. In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging. 2009;2:858–868.
59.
DiehmNShangASilvestroA, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg. 2006;31:59–63.
60.
BurnsDM.Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11–29.
61.
LaclaustraMCasasnovasJAFernandez-OrtizA, et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol. 2016;67:1263–1274.
Leroux-BergerMQueguinerIMacielTT, et al. Pathologic calcification of adult vascular smooth muscle cells differs on their crest or mesodermal embryonic origin. J Bone Miner Res. 2011;26:1543–1553.
64.
AbbasAEZachariasSKGoldsteinJA, et al. Invasive characterization of atherosclerotic plaque in patients with peripheral arterial disease using near-infrared spectroscopy intravascular ultrasound. Catheter Cardiovasc Interv. 2017;90:461–470.
65.
BaumannFFustJEngelbergerRP, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther. 2014;21:44–51.
66.
SchillingerMMinarE.Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag. 2005;1:73–78.
67.
WerkMAlbrechtTMeyerDR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.
68.
ArmstrongEJBrodmannMDeatonDH, et al. Dissections after infrainguinal percutaneous transluminal angioplasty: a systematic review and current state of clinical evidence. J Endovasc Ther. 2019;26:479–489.
69.
RazaviMKMustaphaJAMillerLE.Contemporary systematic review and meta-analysis of early outcomes with percutaneous treatment for infrapopliteal atherosclerotic disease. J Vasc Interv Radiol. 2014;25:1489–1496, 1496.e1-3.
70.
de Athayde SoaresRMatieloMFBrochado NetoFC, et al. Impact of calcification and infrapopliteal outflow on the outcome of endovascular treatment of femoropopliteal occlusive disease. JRSM Cardiovasc Dis. 2019;8:2048004019828941.
71.
van der LugtAGussenhovenEJMaliWP, et al. Effect of balloon angioplasty in femoropopliteal arteries assessed by intravascular ultrasound. Eur J Vasc Endovasc Surg. 1997;13:549–556.
72.
FitzgeraldPJPortsTAYockPG.Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86:64–70.
73.
FanelliFCannavaleAGazzettiM, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
74.
TepeGZellerTSchnorrB, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.
75.
TepeGZellerTAlbrechtT, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.
76.
KobayashiNHiranoKYamawakiM, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg. 2018;67:1151–1158.
ShammasNWToreyJTShammasWJ, et al. Intravascular ultrasound assessment and correlation with angiographic findings demonstrating femoropopliteal arterial dissections post atherectomy: results from the iDissection study. J Invasive Cardiol. 2018;30:240–244.
79.
FujiharaMTakaharaMSasakiS, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–375.
80.
CrippsTRMorganJMRickardsAF.Outcome of extensive coronary artery dissection during coronary angioplasty. Br Heart J. 1991;66:3–6.
81.
HorieKTanakaATaguriM, et al. Impact of prolonged inflation times during plain balloon angioplasty on angiographic dissection in femoropopliteal lesions. J Endovasc Ther. 2018;25:683–691.
82.
ZorgerNMankeCLenhartM, et al. Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on the morphologic results. J Vasc Interv Radiol. 2002;13:355–359.
83.
IliaRCabinHMcConnellS, et al. Coronary angioplasty with gradual versus rapid balloon inflation: initial results and complications. Cathet Cardiovasc Diagn. 1993;29:199–202.
84.
UretskyBFRosanioSLerakisS, et al. A prospective evaluation of angiography-guided coronary stent implantation with high versus very high balloon inflation pressure. Am Heart J. 2000;140:804–812.
85.
GlazierJJVarricchioneTRRyanTJ, et al. Factors predicting recurrent restenosis after percutaneous transluminal coronary balloon angioplasty. Am J Cardiol. 1989;63:902–905.
86.
TanMUrasawaKKoshidaR, et al. Comparison of angiographic dissection patterns caused by long vs short balloons during balloon angioplasty of chronic femoropopliteal occlusions. J Endovasc Ther. 2018;25:192–200.
87.
DickPWallnerHSabetiS, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090–1095.
88.
FeiringAJKrahnMNelsonL, et al. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol. 2010;55:1580–1589.
89.
SiablisDKarnabatidisDKatsanosK, et al. Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results. J Vasc Interv Radiol. 2007;18:1351–1361.
90.
US Food and Drug Administration Notice of Approval: Intact Vascular, Inc; Tack Endovascular System® (6F) (Scaffold, Dissection Repair); March 11, 2019. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180034B.pdf. Accessed November 16, 2019.
91.
ScheinertDScheinertSSaxJ, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315.
92.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
93.
DakeMDAnselGMJaffMR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
94.
BrodmannMWissgottCHoldenA, et al. Treatment of infrapopliteal post-PTA dissection with Tack implants: 12-month results from the TOBA-BTK study. Catheter Cardiovasc Interv. 2018;92:96–105.
NissenSEYockP.Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103:604–616.
97.
ShammasNWToreyJTShammasWJ.Dissections in peripheral vascular interventions: a proposed classification using intravascular ultrasound. J Invasive Cardiol. 2018;30:145–146.
98.
ArmstrongEJAlamSHenaoS, et al. Multidisciplinary care for critical limb ischemia: current gaps and opportunities for improvement. J Endovasc Ther. 2019;26:199–212.
99.
ArmstrongEJShishehborMH.Commentary: Contemporary outcomes of endovascular interventions for peripheral artery disease: the LIBERTY to determine optimal treatment strategies. J Endovasc Ther. 2019;26:155–157.
100.
TopferLASpryC.New technologies for the treatment of peripheral artery disease. April 1, 2018. In: CADTH Issues in Emerging Health Technologies. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health; 2016;172. https://www.ncbi.nlm.nih.gov/books/NBK519606/.
101.
WiechmannBN.Tibial intervention for critical limb ischemia. Semin Intervent Radiol. 2009;26:315–323.
102.
CardonJMJanFVasseurMA, et al. Value of cutting balloon angioplasty for limb salvage in patients with obstruction of popliteal and distal arteries. Ann Vasc Surg. 2008;22:314–318.
103.
ScheinertDGrazianiLPeetersP, et al. Results from the multi-center registry of the novel AngioSculpt scoring balloon catheter for the treatment of infrapopliteal disease. Cardiovasc Revasc Med. 2007;8:147.
104.
BosiersMDelooseKCagiannosC, et al. Use of the AngioSculpt scoring balloon for infrapopliteal lesions in patients with critical limb ischemia: 1-year outcome. Vascular. 2009;17:29–35.
105.
ZhouYZhangZLinS, et al. Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions: a network meta-analysis of randomized controlled trials. J Endovasc Ther. 2020;27:42–59.
106.
AnselGMSampleNSBottiICJr, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. Catheter Cardiovasc Interv. 2004;61:1–4.
107.
BrodmannMHoldenAZellerT.Safety and feasibility of intravascular lithotripsy for treatment of below-the-knee arterial stenoses. J Endovasc Ther. 2018;25:499–503.
108.
AdamsGLDasTLeeMS, et al. Subanalysis of the CONFIRM Registries: acute procedural outcomes in claudicant and critical limb ischemia patients with varying levels of calcification treated for peripheral arterial disease with orbital atherectomy. J Invasive Cardiol. 2015;27:516–520.
109.
MustaphaJAKatzenBTNevilleRF, et al. Propensity score-adjusted comparison of long-term outcomes among revascularization strategies for critical limb ischemia. Circ Cardiovasc Interv. 2019;12:e008097.
110.
ZellerTSixtSSchwarzwalderU, et al. Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device. J Endovasc Ther. 2007;14:232–240.
111.
LairdJRZellerTGrayBH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006;13:1–11.
112.
PiyaskulkaewCParvataneniKBalloutH, et al. Laser in Infrapopliteal and Popliteal Stenosis 2 study (LIPS2): Long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease. Catheter Cardiovasc Interv. 2015;86:1211–1218.
113.
GrayBHDiaz-SandovalLJDieterRS, et al. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84:539–545.
114.
RundbackJChandraPBrodmannM, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser IDE study. Catheter Cardiovasc Interv. 2019;94:1010–1017.
115.
ShammasNWChandraPBrodmannM, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Cardiovasc Revasc Med. 2020;21:86–92.
116.
RastanAMcKinseyJFGarciaLA, et al. One-year outcomes following directional atherectomy of infrapopliteal artery lesions: subgroup results of the prospective, multicenter DEFINITIVE LE trial. J Endovasc Ther. 2015;22:839–846.
117.
AdamsGLKhannaPKStaniloaeCS, et al. Optimal techniques with the Diamondback 360 degrees system achieve effective results for the treatment of peripheral arterial disease. J Cardiovasc Transl Res. 2011;4:220–229.
118.
HeuserRR.Treatment of lower extremity vascular disease: the Diamondback 360 degrees orbital atherectomy system. Expert Rev Med Devices. 2008;5:279–286.
119.
SafianRDNiaziKRunyonJP, et al. Orbital atherectomy for infrapopliteal disease: device concept and outcome data for the OASIS trial. Catheter Cardiovasc Interv. 2009;73:406–412.
120.
ShammasNWLamRMustaphaJ, et al. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther. 2012;19:480–488.
121.
PanaichSSAroraSPatelN, et al. In-hospital outcomes of atherectomy during endovascular lower extremity revascularization. Am J Cardiol. 2016;117:676–684.
122.
BabaevAZavlunovaSAttubatoMJ, et al. Orbital atherectomy plaque modification assessment of the femoropopliteal artery via intravascular ultrasound (TRUTH Study). Vasc Endovascular Surg. 2015;49:188–194.
123.
WeintraubWS.The pathophysiology and burden of restenosis. Am J Cardiol. 2007;100(5a):3k–9k.
124.
RozenmanYGilonDWelberS, et al. Clinical and angiographic predictors of immediate recoil after successful coronary angioplasty and relation to late restenosis. Am J Cardiol. 1993;72:1020–1025.
125.
BermejoJBotasJGarcíaE, et al. Mechanisms of residual lumen stenosis after high-pressure stent implantation. Circulation. 1998;98:112–118.
126.
CaixetaAMArieSSandoli de BritoFJr, et al. Analysis of elastic retraction in the 1st 15 minutes after coronary balloon angioplasty [in Portuguese]. Arq Bras Cardiol. 1996;66:5–9.
127.
BermejoJBotasJGarciaE, et al. Mechanisms of residual lumen stenosis after high-pressure stent implantation: a quantitative coronary angiography and intravascular ultrasound study. Circulation. 1998;98:112–118.
128.
BrodmannMFroehlichHDorrA, et al. Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arteries in critical limb ischemia. Vasa. 2011;40:482–490.
129.
RandonCJacobsBDe RyckF, et al. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol. 2010;33:260–269.
130.
FarbAWeberDKKolodgieFD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980.
131.
BosiersMHartJPDelooseK, et al. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular. 2006;14:63–69.
132.
SiablisDKarnabatidisDKatsanosK, et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther. 2007;14:241–250.
133.
EpsteinSESpeirEUngerEF, et al. The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol. 1994;23:1278–1288.
134.
SchmidtAUlrichMWinklerB, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76:1047–1054.
135.
BaumannFWillenbergTDoDD, et al. Endovascular revascularization of below-the-knee arteries: prospective short-term angiographic and clinical follow-up. J Vasc Interv Radiol. 2011;22:1665–1673.
136.
RastanABrechtelKKrankenbergH, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60:587–591.
137.
BaumannFOzdobaCGröchenigE, et al. The importance of patency in patients with critical limb ischemia undergoing endovascular revascularization for infrapopliteal arterial disease. Front Cardiovasc Med. 2014;1:17.
138.
GearyRLClowesAW. Epidemiology and pathogenesis of restenosis. In: Essentials of Restenosis. New York: Springer; 2007:7–28.
139.
CasscellsWEnglerDWillersonJT.Mechanisms of restenosis. Tex Heart Inst J. 1994;21:68–77.
140.
PakalaRWillersonJTBenedictCR.Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997;96:2280–2286.
141.
MianoJMVlasicNTotaRR, et al. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol. 1993;142:715–724.
142.
RiessenRWightTNPastoreC, et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation. 1996;93:1141–1147.
143.
MintzGSPopmaJJPichardAD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35–43.
144.
MoussaIMosesJDi MarioC, et al. Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis?Am J Cardiol. 1999;83:1012–1017.
145.
BhargavaBKarthikeyanGAbizaidAS, et al. New approaches to preventing restenosis. BMJ. 2003;327:274–279.
146.
BosiersMScheinertDPeetersP, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390–398.
147.
ScheinertDKatsanosKZellerT, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290–2295.
148.
BaumannFEngelbergerRPWillenbergT, et al. Infrapopliteal lesion morphology in patients with critical limb ischemia: implications for the development of anti-restenosis technologies. J Endovasc Ther. 2013;20:149–156.
149.
BosiersMDelooseKVermassenF, et al. The use of the cryoplasty technique in the treatment of infrapopliteal lesions for critical limb ischemia patients in a routine hospital setting: one-year outcome of the Cryoplasty CLIMB Registry. J Cardiovasc Surg (Torino). 2010;51:193–202.
150.
KarnabatidisDKatsanosKSpiliopoulosS, et al. Incidence, anatomical location, and clinical significance of compressions and fractures in infrapopliteal balloon-expandable metal stents. J Endovasc Ther. 2009;16:15–22.
151.
DelooseKCallaertJ.Less is more: the “as less as reasonably achievable stenting” (ALARAS) strategy in the femoropopliteal area. J Cardiovasc Surg (Torino). 2018;59:495–503.
MustaphaJABrodmannMGeraghtyPJ, et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol. 2019;31:205–211.
154.
ZhouYLinSZhangZ, et al. A network meta-analysis of randomized controlled trials comparing treatment modalities for infrapopliteal lesions in critical limb ischemia. Ann Vasc Surg. 2019;60:424–434.
155.
ZellerTBaumgartnerIScheinertD, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576.
156.
ZellerTBeschornerUPilgerE, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614–1622.
157.
HertenMStahlhoffSImmB, et al. Drug-coated balloons in the treatment of peripheral artery disease (PAD). History and current level of evidence [in German]. Radiologe. 2016;56:240–253.
158.
SchulteKLPilgerESchellongS, et al. Primary self-expanding nitinol stenting vs balloon angioplasty with optional bailout stenting for the treatment of infrapopliteal artery disease in patients with severe intermittent claudication or critical limb ischemia (EXPAND Study). J Endovasc Ther. 2015;22:690–697.
159.
HaddadSEShishaniJMQtaishI, et al. One year primary patency of infrapopliteal angioplasty using drug-eluting balloons: single center experience at King Hussein Medical Center. J Clin Imaging Sci. 2017;7:31.
160.
SpreenMIMartensJMKnippenbergB, et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc. 2017;6:e004877.
161.
ZellerTBaumgartnerIScheinertD, et al. IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials. 2014;15:63.
162.
LiistroFPortoIAngioliP, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.
163.
RandTLammerJRabbiaC, et al. Percutaneous transluminal angioplasty versus turbostatic carbon-coated stents in infrapopliteal arteries: InPeria II trial. Radiology. 2011;261:634–642.
164.
TepeGSchmehlJHellerS, et al. Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers—The BELOW Study. J Cardiovasc Surg (Torino). 2010;51:203–212.
165.
RandTBasileACejnaM, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc Intervent Radiol. 2006;29:29–38.
166.
RastanATepeGKrankenbergH, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–2281.
167.
BosiersMPeetersPD’ArchambeauO, et al. AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32:424–435.
168.
FalkowskiAPoncyljuszWWilkG, et al. The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries. Eur Radiol. 2009;19:966–974.
169.
SiablisDKitrouPMSpiliopoulosS, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048–1056.
170.
AllieDEHebertCJPatlolaRR, et al. Optimizing infrapopliteal interventions with vessel sizing therefore treating the infrapops like the LAD: a safety and feasibility analysis of the Metricath system. Abstract presented at: TCT 2008, October 12–17, 2008; Washington, DC.
171.
ChoiHWBerwickZCSulkinMS, et al. Optimization of peripheral vascular sizing with conductance guidewire: theory and experiment. PLoS One. 2017;12:e0168886.
172.
ArthursZMBishopPDFeitenLE, et al. Evaluation of peripheral atherosclerosis: a comparative analysis of angiography and intravascular ultrasound imaging. J Vasc Surg. 2010;51:933–938.
173.
KatzenBBenenatiJBeckerG, et al. Role of intravascular ultrasound in peripheral atherectomy and stent deployment. Circulation. 1991;84(suppl II):2152.
174.
ShammasNWShammasWJJones-MillerS, et al. Optimal vessel sizing and understanding dissections in infrapopliteal interventions: data from the iDissection Below-the-Knee Study. J Endovasc Ther. 2020;27(4):575–580.
175.
LichtenbergMWojczikHStahlhoffS, et al. Practical applications of Tack implants for infrainguinal dissection repair: a single-center experience. J Endovasc Ther. 2020;27:86–93.
